
Sign up to save your podcasts
Or


What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
By HBR Presents / Brian Kenny4.5
190190 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.

386 Listeners

1,470 Listeners

105 Listeners

154 Listeners

1,099 Listeners

3,992 Listeners

1,379 Listeners

742 Listeners

107 Listeners

176 Listeners

42 Listeners

828 Listeners

678 Listeners

221 Listeners

79 Listeners

170 Listeners

82 Listeners